Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455423 | 0.80 | CNR1 (0.39) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL14172486 | 0.76 | ACHE (0.38) | ALDH1A1CNR1CNR2 | |
| SCHEMBL21993465 | 0.74 | ALDH1A1 (0.48) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL13369042 | 0.74 | TSHR (0.37) | CNR1CNR2 | |
| SCHEMBL18114062 | 0.71 | TSHR (0.36) | ALDH1A1TDP1 | |
| SCHEMBL11225137 | 0.70 | ALDH1A1 (0.45) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL6535133 | 0.70 | DRD2 (0.31) | — | |
| SCHEMBL18613383 | 0.70 | MAPT (0.37) | ALDH1A1KDM4ELMNAMAPTTDP1 | |
| SCHEMBL18114060 | 0.70 | ELANE (0.41) | ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL18114063 | 0.70 | INPPL1 (0.38) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691845-A4 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1691845-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | Bristol-Myers Squibb Pharma Company (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023314-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | MMP1, MMP10, MMP8 | ALDH1A1 1089/4885KDM4E 4514/4885LMNA 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.